Low-Molecular-Weight Heparin Plus Insulin in Hypertriglyceridemic Acute Pancreatitis
JAMA Network Open · 07.11.2025 · 8 (11) · e2542124
DOI: 10.1001/jamanetworkopen.2025.42124 ↗Kurz gefasst
Äquivalenzstudie in der Zeitschrift JAMA Network Open, online erschienen am 07.11.2025. Verfasst von Wenhua He und 44 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China. Hauptthemen laut MEDLINE: Heparin, Low-Molecular-Weight, Hypertriglyceridemia, Hypoglycemic Agents, Insulin. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Although insulin is widely used for early lipid lowering in hypertriglyceridemic acute pancreatitis, the clinical benefit of heparin combined with insulin remains unclear.
Objective
To examine whether low-molecular-weight heparin (LMWH) combined with insulin is superior to insulin alone in improving clinical outcomes in hypertriglyceridemic acute pancreatitis. Design, Setting, and Participants This multicenter, open-label, parallel-group, superiority randomized clinical trial was conducted from September 21, 2019, to April 2, 2023, across 13 tertiary hospitals in China. The duration of follow-up was 30 days after randomization. Patients aged 18 to 85 years were eligible if they met the diagnostic criteria for acute pancreatitis, presented with baseline serum triglyceride levels between 1000 and 3550 mg/dL, and were admitted within 48 hours of symptom onset.
Interventions
Participants received either subcutaneous LMWH (4000 IU every 12 hours for 3 days) plus insulin (LMWH plus insulin group) or insulin alone (insulin group). Main Outcomes and Measures The primary end point was a composite of new-onset organ failure (defined as organ failure occurring after randomization but absent during the 24-hour prerandomization period) and/or all-cause mortality within 30 days after randomization.
Results
Among 533 randomized patients (median [IQR] age, 39 [33-46] years; 406 [76.2%] male), 264 were randomized to LMWH plus insulin and 269 to insulin alone. The primary end point occurred in 66 (25.0%) of the LMWH and insulin group vs 76 (28.3%) of the insulin group (relative risk [RR], 0.89; 95% CI, 0.67-1.17; P = .40). Both groups achieved the triglyceride target (<500 mg/dL) in a median (IQR) of 2 (1-3) days ( P = .94). Safety outcomes were similar between groups, including new-onset bleeding events (RR, 0.61; 95% CI, 0.15-2.53; P = .73), triglyceride rebound (RR, 0.53; 95% CI, 0.28-1.01; P = .05), and drug-related adverse events (RR, 0.79; 95% CI, 0.30-2.10; P = .64). Conclusions and Relevance In this randomized clinical trial, the combination of LMWH and insulin failed to demonstrate superior efficacy vs insulin alone in patients with hypertriglyceridemic acute pancreatitis. LMWH might not be necessary for early lipid-lowering in hypertriglyceridemic acute pancreatitis. Trial Registration ChiCTR.org.cn Identifier: ChiCTR1900023640
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
- Department of Gastroenterology, Xinyu People's Hospital, Xinyu, China.
- Department of Gastroenterology, Fuzhou First People's Hospital, Fuzhou, China.
- Department of Emergency, Ganzhou People's Hospital, Ganzhou, China.
- Department of Gastroenterology, Pingxiang People's Hospital, Pingxiang, China.
- Department of Gastroenterology, Jingdezhen First People's Hospital, Jingdezhen, China.
Zitieren
APA
He, W., Ding, L., Liu, Z., Hua, M., Zhou, Y., Gong, M., Sheng, J., Wu, X., Fan, H., Shu, H., Wang, R., Xun, L., Huang, C., Guo, F., Cao, C., Zhan, Z., Chen, H., Qian, X., Liu, Q., …, & Chinese Acute Pancreatitis Clinical Trials Group (CAPCTG) (2025). Low-Molecular-Weight Heparin Plus Insulin in Hypertriglyceridemic Acute Pancreatitis. JAMA Network Open, 8(11), e2542124. https://doi.org/10.1001/jamanetworkopen.2025.42124
Vancouver
He W, Ding L, Liu Z, Hua M, Zhou Y, Gong M, et al. Low-Molecular-Weight Heparin Plus Insulin in Hypertriglyceridemic Acute Pancreatitis. JAMA Network Open. 2025;8(11):e2542124. doi:10.1001/jamanetworkopen.2025.42124
BibTeX
@article{He2025,
author = {He, Wenhua and Ding, Ling and Liu, Zhijun and Hua, Ming'e and Zhou, Yuming and Gong, Min and Sheng, Jinyi and Wu, Ximing and Fan, Huizhen and Shu, Hongchun and Wang, Ruilan and Xun, Linting and Huang, Caibin and Guo, Feng and Cao, Chunshui and Zhan, Zuan and Chen, Huifang and Qian, Xing and Liu, Qinghong and Li, Qiang and Tang, Zhihua and Xiong, Yanyan and Xie, Ping and Yu, Bingjun and Wan, Jianhua and Ke, Huajing and Wu, Yao and Hu, Yang and Ai, Jiaoyu and Huang, Xin and Lei, Yupeng and Xiong, Huifang and Liu, Zhijian and Zhu, Yong and Luo, Lingyu and Xia, Liang and Ke, Lu and Cai, Wenhao and Huang, Wei and Li, Weiqin and Windsor, John and Sutton, Robert and Lv, Nonghua and Zhu, Yin and Chinese Acute Pancreatitis Clinical Trials Group (CAPCTG), Chinese Acute Pancreatitis Clinical Trials Group (CAPCTG)},
title = {Low-Molecular-Weight Heparin Plus Insulin in Hypertriglyceridemic Acute Pancreatitis},
journal = {JAMA Network Open},
year = {2025},
volume = {8},
number = {11},
pages = {e2542124},
doi = {10.1001/jamanetworkopen.2025.42124}
}
EUVIMED